Lamisil- Challengers success.docVIP

 PAGE \* MERGEFORMAT 12 Lamisil: Challenger’s success US Tianjin SmithKline Pharmaceutical Co., Ltd., Gray Advertising Co., Ltd. Lamisil enter the market process is a small brand new entrants challenge the market leader in the brand story. Following the premise of the full market research conditions, Lamisil athlete’s foot found in the Chinese medicine market, a potential law: China’s a lot of athlete’s foot patients were died, the drug also has inertia, so Lamisil In fact, to overcome the consumer inert. They thus found the most important entry point. As a result, Lamisil unconventional attitude to access to markets, share, and be successful. Market China belongs to the athlete’s foot-prone areas, the national average incidence rate of nearly 30% in some high-prone areas such as southern and eastern coastal areas, the incidence rate as high as 60%. Therefore, the higher the penetration rate of athlete’s foot treatment rates also show high, about 90% of patients will take the initiative to treat athlete’s foot, among whom 75% would choose to use Western medicine as the preferred product. Competition from the market perspective, athlete’s foot medicine on the market is not only the existence of nearly a decade of history and credibility of the national leading brands, that is, from Johnson amp;amp; Johnson’s Miconazole, which occupies more than 60% of the market share; and the potential The market capacity has also attracted a considerable influence on a large number of local brands, such as the Central Lee, Fu-chi, the United States grams and so on, to varying degrees, they also divide up the market. At present, the biggest problem facing patients with athlete’s foot are: athlete’s foot and high recurrence rate in patients with chronic illness to become troubled, but this is all the athlete’s foot medicines can not really solve the area. A long life cycle of existing drugs, medication, therapeutic effects. Because of the athlete’s foot understand more, mos